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Background: Some patients with Takotsubo cardiomyopathy (TTC) develop cardiogenic shock due to left
ventricular outflow tract (LVOT) obstruction – there is, however, a paucity of data regarding this condition.
Methods: Prevalence, associated factors and management implications of LVOT obstruction in TTC was explored,
based on two-year data from two Belgian heart centres.
Results: A total of 32 patients with TTC were identified out of 3,272 patients presenting with troponin-positive acute
coronary syndrome. In six patients diagnosed with TTC (19%), a significant LVOT obstruction was detected by
transthoracic echocardiography. Patients with LVOT obstruction were older and had more often septal bulging, and
presented more frequently in cardiogenic shock as compared to those without LVOT obstruction (P < 0.05). Moreover,
all patients with LVOT obstruction showed systolic anterior motion (SAM) of the anterior mitral valve leaflet, which was
associated with a higher grade of mitral regurgitation (2.2±0.7 vs. 1.0±0.6, P<0.001). Adequate therapeutic management
including fluid resuscitation, cessation of inotropic therapy, intravenous β-blocker, and the use of intra-aortic balloon
pump resulted in non-inferior survival in TTC patients with LVOT obstruction as compared to those without LVOT
obstruction.
Conclusions: TTC is complicated by LVOT obstruction in approximately 20% of cases. Older age, septal
bulging, SAM-induced mitral regurgitation and hemodynamic instability are associated with this condition.
Timely and accurate diagnosis of LVOT obstruction by echocardiography is key to successful management of
these TTC patients with LVOT obstruction and results in a non-inferior outcome as compared to those patients without
LVOT obstruction.
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Cardiogenic shockBackground
Takotsubo cardiomyopathy (TTC) – also called apical
ballooning syndrome – is an increasingly reported clin-
ical entity characterized by transient severe systolic heart
failure that mimics an acute myocardial infarction in the
absence of obstructive coronary artery disease [1,2]. This
condition predominantly affects postmenopausal women* Correspondence: ole.debacker@gmail.com
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unless otherwise stated.and emotional/physical stress at onset is common,
although a triggering event is not always present. Postulated
pathogenic mechanisms include multivessel epicardial
vasospasm, coronary microvascular dysfunction, and
catecholamine-triggered myocyte injury. Other studies
hypothesize that in the presence of increased catechol-
amine levels, a dynamic intraventricular pressure gradient
develops, resulting in subendocardial ‘stunning’ of the left
ventricular (LV) apical region [1-6].
Importantly, some patients with TTC develop cardio-
genic shock due to severe systolic dysfunction or leftral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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however, a paucity of data regarding this latter condition.
Accordingly, we explored the prevalence and characteristics
of TTC in a population presenting with troponin-positive
acute coronary syndrome (ACS) – with focus on LVOT
obstruction and its management.
Methods
Study population
The study population consisted of all patients referred
with troponin-positive ACS to two high-volume cath-
eterisation laboratories (Ghent University Hospital, AZ
Sint-Jan Bruges) in Belgium in a period of 24 consecu-
tive months. The diagnosis of TTC was based on the
Mayo-criteria [5]: (1) transient hypokinesia, akinesia, or
dyskinesia of the LV mid segments with or without
apical involvement – regional wall motion abnormalities
extend beyond a single epicardial distribution; (2) ab-
sence of obstructive coronary artery disease or angio-
graphic evidence of acute plaque rupture; (3) new
electrocardiographic abnormalities (either ST-segment
elevation and/or T-wave inversion) or elevated cardiac
troponin; (4) absence of a pheochromocytoma, myocar-
ditis or hypertrophic cardiomyopathy.
Clinical, biochemical, electrocardiographic, echocardio-
graphic and angiographic data were retrospectively col-
lected. Clinical data included demographics, cardiovascular
risk factors, presenting symptoms and emotional or
physical triggers. The peak Troponin-T (TnT)-value
was measured as a marker of myocyte necrosis.
Coronary and LV angiography were performed within
72 hours after onset of symptoms. LV angiograms
were used to calculate LV ejection fraction (LVEF)
and detect regional wall motion abnormalities. Based
on review of the echocardiographic images, TTC
patients were further dichotomized depending on the
presence of significant LVOT obstruction. Due to the
retrospective nature of this study, the choice of treat-
ment was at the discretion of the treating physician.
Approval for this study was provided by the local
Ethical Committee of Ghent University Hospital
(Ghent, Belgium) and all patients gave written in-
formed consent for the use of anonymous clinical,
procedural, and follow-up data.
Echocardiography
Within 24 hours of admission, all patients with suspected
TTC underwent transthoracic echocardiography. A follow-
up echocardiographic study was performed in most
patients at random intervals, most often at day 4–14 (at
discharge), at 4–8 weeks, and approximately one year after
the acute phase. Standard gray-scale and color-Doppler
images were acquired with ECG-triggering and in cine-loop
format for on-line analysis. In particular, septal wallthickness was measured at parasternal long axis view and
septal bulging was defined as basal interventricular septum
(IVS) thickness ≥12 mm. The same view was used for
detection of systolic anterior motion (SAM) of the anterior
mitral valve leaflet. LVEF was evaluated using Biplane
Simpson method, as recommended [7]. In addition, re-
gional wall motion abnormalities were assessed. Color
Doppler was used to identify turbulent flow, suggesting
increased pressure gradient in the LV. To further identify
significant peak pressure gradients (defined as >20 mmHg),
pulsed wave Doppler was used, set above the mitral leaflets
tips (assessment of intraventricular pressure gradient) and
into the LVOT (assessment of LVOT pressure gradient/
obstruction). The final gradient was calculated using the
modified Bernoulli equation based on maximal flow vel-
ocities derived from continuous wave Doppler imaging.
As previously reported, mitral regurgitation (MR) severity
(grade 0–4) was assessed using an integrative approach
based on vena contracta width, color Doppler jet area, or
by quantitative approach whenever possible (Doppler-
volumetric/proximal isovelocity surface area) [8].
Statistical analysis
Continuous variables are reported as means ± standard
deviation, unless otherwise specified. Categorical data are
reported as absolute values and percentages. Continuous
and categorical variables were compared by (un)paired t
test, χ2 test and Fisher test, as appropriate. All data were
analysed using SPSS version 20.0 (SPSS Inc., Chicago, IL,




Out of 3,272 patients with troponin-positive ACS referred
for coronary angiography, a total of 32 patients were iden-
tified with TTC – indicating an overall prevalence of 1.0%
(Figure 1).
As shown in Table 1, TTC patients were predominantly
older women (66 ± 15 years, 94% female). The overall
cardiovascular risk profile was rather low, in line with
the absence of significant coronary artery lesions on
coronary angiography. The most common presenting
symptoms were chest pain (n = 17; 53%), respiratory
distress (n = 8; 25%), and cardiogenic shock (n = 5;
16%). Two other patients presented with ventricular
tachycardia (VT) and fibrillation (VF), both were suc-
cessfully resuscitated. In 22 patients, a stressful event
preceding the acute phase of TTC could be identified.
These events were considered emotionally mediated
in 9 patients (28%) or alternatively due to a physical
trigger in 13 other patients (41%) – these circum-
stances are detailed in Additional file 1: Table S1. On
admission, ST-segment elevation mimicking acute
Figure 1 Prevalence of takotsubo cardiomyopathy in a
population presenting with troponin-positive acute
coronary syndrome.
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the patients (n = 15, 47%), while 16 patients (50%) presented
with other ST/T abnormalities. On admission, TnT was
elevated in 28 patients (88%) and peak in-hospital TnT was
0.93 ± 0.90 ng/mL (range 0.1 to 3.6 ng/mL). Echocardiog-
raphy and LV angiography revealed a typical pattern of
‘apical ballooning’ with akinesia of the mid/apical LV seg-
ments and compensatory hyperkinesia of the basal segments
in the majority of patients (n = 30). Only two patients pre-
sented with ‘inverse’ TTC or mid-ventricular ballooning, ie.
akinesia of the mid LV segments. Per patient clinical,
biochemical, electro-/echo-cardiographic and angiographic
data are available in Additional file 1: Table S1.
Patients without vs. with LVOT obstruction
As shown in Table 1, a total of six patients (19%) were iden-
tified with significant LVOT obstruction and no patients
were found to have a significant intraventricular pressure
gradient. The TTC patient population was dichotomized
based on the absence or presence of LVOT obstruction.
The latter group was significantly older and presented more
often with hemodynamic instability as compared to patients
without LVOT obstruction (n = 26, 81%). In addition, ahigher basal IVS thickness leading to increased prevalence
of septal bulging was found. Patients with LVOT obstruc-
tion all showed SAM and consequently more severe MR as
compared to patients without LVOT obstruction (Table 1).
Of note, none of these patients had a familial history of
hypertrophic cardiomyopathy. Both patient groups without
vs. with LVOT obstruction had similar peak TnT and mean
LVEF at admission. No LVOT obstruction was found in the
two patients that were resuscitated because of VT/VF.
LVOT obstruction and therapeutic management
Similar proportions of TTC patients without vs. with
LVOT obstruction were initially treated with i.v. inotropics
(27% vs. 33%, respectively; Table 1). However, inotropic
therapy was immediately stopped in the two patients with
LVOT obstruction from the moment of diagnosis by
echocardiography. Patients without LVOT obstruction
were given inotropic agents for a maximum duration of
five days. In addition, an intra-aortic balloon pump (IABP)
was used in 9 TTC patients (28%) because of severe systolic
dysfunction (LVEF < 35%, n = 4), LVOT obstruction (n =
2), or non-specified reason(s) (n = 3). Only two patients
received β-blocker i.v. – both patients were diagnosed with
severe LVOT obstruction (pressure gradient ≥40 mmHg).
Per patient therapeutical management data are available in
Additional file 1: Table S1.
Patient outcome
A total of two TTC patients (32, 6%) without LVOT
obstruction died in the acute setting due to refractory
cardiogenic shock (n = 1) or acute respiratory distress
syndrome (n = 1, see Additional file 1: Table S1). No
mortality occurred in the group of patients diagnosed
with LVOT obstruction. There was no residual dy-
namic LVOT pressure gradient detected at discharge
in any of the patients initially presenting with LVOT
obstruction. In accordance, there was no more SAM
of the anterior mitral valve leaflet, resulting in an import-
ant reduction of MR severity (mean MR grade 1.2 ± 0.6 vs.
2.2 ± 0.7). Recovery of LV systolic function – defined as
LVEF ≥55% – was observed within 19 ± 12 days (range 5
to 42 days – based on data obtained in 24 patients, see
Additional file 1: Table S1). At medium to long-term
follow-up, two patients experienced recurrence of TTC at
0.9 and 5.2 years after the first episode, while on oral β-
blocker therapy. No evident relation was found between
baseline clinical features, ECG pattern, TnT levels, and/or
outcome (data not shown).
Discussion
The main findings of this study are: (1) LVOT obstruction
is not uncommon in TTC, (2) patients with LVOT ob-
struction have a different clinical and echocardiographic
baseline profile, and (3) an adequate and tailored therapy
Table 1 Baseline characteristics of patients with takotsubo cardiomyopathy
Total (n = 32) No LVOT obstruction (n = 26) LVOT obstruction (n = 6) P-value
Age (years), mean ± SD 66 ± 15 64 ± 15 77 ± 7 0.047*
Female, n (%) 30 (93.8) 24 (92.3) 6 (100) 1.000
Risk factors, n (%)
Hypertension 18 (56.2) 13 (50.0) 5 (83.3) 0.196
Hypercholesterolemia 8 (25.0) 5 (19.2) 3 (50.0) 0.296
Diabetes mellitus 3 (9.4) 2 (7.7) 1 (16.7) 1.000
Trigger, n (%)
Physical stress 13 (59.1) 12 (46.2) 1 (16.7) 0.387
Emotional stress 9 (40.9) 8 (30.8) 1 (16.7) 0.850
Presenting symptom, n (%)
Chest pain 17 (53.1) 15 (57.7) 2 (33.3) 0.383
Respiratory distress 8 (25.0) 7 (26.9) 1 (16.7) 1.000
Cardiogenic shock 5 (15.6) 2 (7.7) 3 (50.0) 0.034*
VT/VF 2 (6.2) 2 (7.7) 0 (0.0) 1.000
ECG, n (%) or mean ± SD
ST-elevation 17 (53.1) 13 (50.0) 4 (66.7) 0.659
ST-depression/negT 14 (43.8) 12 (46.2) 2 (33.3) 0.672
QRS (ms) 97 ± 10 98 ± 10 92 ± 7 0.179
QTc (ms) 421 ± 30 418 ± 27 435 ± 43 0.223
TnT (ng/mL), mean ± SD 0.93 ± 0.90 0.99 ± 0.96 0.68 ± 0.50 0.462
TTE, n (%) or mean ± SD
LVEF (%)# 40.5 ± 10.3 41.1 ± 11.0 38.0 ± 5.8 0.512
IVS (mm) 10.8 ± 1.7 10.5 ± 1.4 12.0 ± 2.1 0.044*
Septal bulge 12 (37.5) 7 (26.9) 5 (83.3) 0.018*
SAM 6 (18.8) 0 (0.0) 6 (100) < 0.001*
MR grade 1.25 ± 0.73 1.0 ± 0.6 2.2 ± 0.7 < 0.001*
Therapeutic options, n (%)
Inotropics i.v. 9 (28.1) 7 (26.9) 2 (33.3) 1.000
Beta-blocker i.v. 2 (6.2) 0 (0.0) 2 (33.3) 0.030*
IABP 9 (28.1) 7 (26.9) 2 (33.3) 1.000
Recuperation, mean ± SD
LVEF ≥55% (days) 19 ± 12 18 ± 11 23 ± 16 0.479
Continuous variables are reported as means ± SD.; categorical variables are reported as absolute values and percentages. Continuous and categorical variables
were compared by use of (un)paired t test, χ2 test and Fisher test, as appropriate. Abbreviations: VT/VF ventricular tachycardia/fibrillation, TnT troponin T, TTE
transthoracic echocardiography, LVEF left ventricular ejection fraction, IVS interventricular septum thickness, SAM, systolic anterior motion, MR, mitral regurgitation,
IABP intraaortic balloon pump. #LVEF as calculated on LV angiogram (and confirmed on transthoracic echocardiography).
*P-value < 0.05.
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non-inferior outcome as compared to those without
LVOT obstruction.
In line with previous findings [3-5,9], we report an overall
prevalence of TTC of 1.0% in patients presenting with
troponin-positive ACS – this prevalence is even higher
when considering only female patients, as TTC predomin-
antly occurs in postmenopausal women. TTC is not neces-
sarily a benign disease, considering the occurence of
cardiogenic shock, life-threatening arrhythmias, and suddencardiac death [10-12] as well as persistent wall motion
abnormalities with delayed recovery [13,14]. Interestingly,
we noted a co-incidence of LVOT obstruction in approxi-
mately one out of five subjects (19%) presenting with TTC –
this is in line with other studies reporting a 5-25%
prevalence of LVOT obstruction in TTC patients [6,15-18].
In addition, our study confirms the presence of a
characteristic baseline profile in TTC patients with LVOT
obstruction – as previously reported by El Mahmoud
et al. [18] – and adds data regarding trigger, presenting
Figure 2 Diagnostic evaluation and treatment of a patient with takotsubo cardiomyopathy and severe left ventricular outflow tract
(LVOT) obstruction. A 74-year old woman was admitted with ST-segment elevation in the precordial leads and in cardiogenic shock. Panel A-B: Left
ventricular angiography shows a typical pattern of ‘apical ballooning’ at systole (panel A) when compared to diastole (panel B). Panel C: Intra-aortic
balloon pump counter-pulsation therapy was initiated in the cath-lab. Because of refractory shock, dobutamine (dobu) and norepinephrine (levo) were
started at the ICU. Cessation of inotropic therapy after echocardiographic diagnosis of LVOT obstruction resulted in recovery of blood pressure. Panel
D: Severe LVOT obstruction was identified on continuous wave Doppler echocardiography (end-systolic pressure gradient 149 mmHg). Panel E:
Echocardiography confirming the presence of apical akinesia or ‘apical ballooning’. HR: heart rate (beats per minute); BP: blood pressure (mmHg).
The white arrows indicate ‘apical ballooning’; the yellow arrows indicate systolic anterior motion (SAM)-induced mitral regurgitation.
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with LVOT obstruction were older and nearly all presented
a septal bulge, associated with SAM of the mitral valve and
significant MR. This morphological pattern of the IVS is
mostly present in elderly patients with a medical history of
hypertension and seems to be a predisposing and/or
contributing factor to the development of LVOT
obstruction in TTC patients, thereby mimicking a
pattern of hypertrophic obstructive cardiomyopathy.
In 2001, Villareal et al. reported for the first time
LVOT obstruction in three patients with TTC [19].
Other groups could confirm these pathologic find-
ings, especially in women with a mid-ventricular
septal thickening, suggesting that this could be an
important factor in the development of this syn-
drome [20]. It was hypothesized that in the presence
of increased concentrations of catecholamines –
caused by a stressful event – this mid-ventricular
septal thickening could lead to the development of a
severe transient LV mid-cavity obstruction, resultingin ‘apical stunning’ (unrelated to a specific coronary
artery territory). Still, it remains unclear whether the
observed LVOT pressure gradient is a ‘consequence’
rather than a ‘cause‘ of TTC, also given the fact that
LVOT obstruction does not occur in all TTC patients [21].
Remarkably, approximately half of our TTC patients with
LVOT obstruction exhibited cardiogenic shock at admis-
sion, suggesting that this mechanism plays a detrimental
role in the further clinical evolution of this disease. Of
note, none of the TTC patients with LVOT obstruction
died in our cohort and all patients had full LVEF recovery,
which was accompanied by disappearance of the dynamic
LVOT pressure gradient, disappearance of SAM and MR
reduction.
Clinical implications
Identification of TTC patients at risk for LVOT obstruction
is of critical importance as its presence has important ther-
apeutical management implications. In particular, older age
and presence of septal bulge are associated with LVOT
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addition, hemodynamic instability at presentation should
raise suspicion of LVOT obstruction in these patients. In
fact, the use of inotropic agents should be avoided in
patients with LVOT obstruction, particularly when
hemodynamic instability is present, as inotropic therapy may
increase LVOT obstruction and worsen cardiogenic shock
[22-25]. Administration of β-blockers has been shown not to
be detrimental and potentially of benefit to alleviate LVOT
obstruction in these patients [26]. However, patients without
significant LVOT obstruction who are hypotensive due to
severe LV dysfunction can be treated with inotropes such as
dobutamine and dopamine, and in these cases, use of β-Figure 3 Therapeutic management of takotsubo cardiomyopathy – ablockers is contraindicated [22]. Therefore, we suggest that
transthoracic echocardiography should be systematically
performed at admission in all patients presenting with
TTC in order to identify presence of LVOT obstruc-
tion, especially when additional risk factors are
present. The importance of echocardiography for the
successful management of TTC patients in cardio-
genic shock is illustrated by patient case #12, in
which the detection of severe LVOT obstruction –
evidenced by a peak end-systolic pressure gradient of
149 mmHg – led to cessation of all inotropic support
and, ultimately, the survival of this patient who was
admitted with profound cardiogenic shock (Figure 2).practical flow chart.
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propose a practical flow chart for the management of
patients with TTC in Figure 3. In general, the initial
management of TTC should be largely supportive, in-
cluding adequate hydration in non-acute heart failure
patients and an attempt to alleviate the triggering
physical or emotional stress. When confronted with
TTC patients with hypotension/shock, urgent echocar-
diographic evaluation is indispensable in order to evaluate
LV systolic function as well as the potential presence of
LVOT obstruction. In patients with hypotension and
moderate-to-severe LVOT obstruction, inotropic agents
and vasodilators should be avoided and use of β-
blockers warrants consideration. In patients with se-
vere hypotension or refractory shock, the use of IABP
may be considered. As there is a potential risk that
afterload reduction from the IABP may worsen the
degree of obstruction in patients with LVOT obstruc-
tion, we recommend evaluating the LVOT gradient in
the presence and absence of IABP counter-pulsation
Controlled data defining the optimal medical regimen
for TTC patients after the acute setting are lacking.
However, it is reasonable to treat these patients with
standard medications for LV systolic dysfunction until
LV systolic function fully recovers, including angiotensin
converting enzyme inhibitors, β-blockers and diuretics
as appropriate. Moreover, a short course of low molecu-
lar weight heparins to prevent LV apical thrombus
formation may be recommended [22]. Data that would
support the persistent use of oral β-blocker therapy in
order to prevent long-term re-occurence of TTC are
currently not available.Study limitations
We recognize this study is hampered by its retrospective
and observational nature. In addition, assessment of
independent predictors of LVOT obstruction is not pos-
sible, given the limited number of cases presenting with
LVOT obstruction. However, our results are hypothesis
generating and the impact of LVOT obstruction on
therapeutic management and outcome of patients pre-
senting with TTC needs further prospective study.Conclusions
LVOT obstruction complicating TTC is a common
transient phenomenon, suspected if presence of
hemodynamic instability. Older age and presence of a
septal bulge are predisposing factors for LVOT obstruction
development. Timely and accurate diagnosis by echocardi-
ography is key to successful and tailored management of
TTC with LVOT obstruction and results in non-inferior
outcome as compared to TTC patients without this
condition.Additional file
Additional file 1: Detailed characteristics of all patients presenting
with Takotsubo cardiomyopathy (n = 32).
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